世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037443

世界の医薬品開発製造受託機関(CDMO)市場:規模と動向、2029年までの予測

Daedal Research

Global Contract Development and Manufacturing Organization (CDMO) Market: Size and Trends with Forecast up to 2029

発刊日 2024/02

言語英語

体裁PDF/180ページ

ライセンス/価格180ページ

0000037443

Single 2,450USD

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

世界の医薬品開発製造受託機関(CDMO)市場:タイプ別(化学医薬品および生物製剤)、製品別(API/原薬、医薬品製造(投与量および製剤開発を含む)および包装)、調達別(社内および外部委託)、アプリケーション別(腫瘍学、心血管疾患、糖尿病、ホルモン、緑内障など)、地域別、規模別、COVID-19の影響を伴う動向、および2029年までの予測

世界の開発製造受託機関(CDMO)市場の規模は、2023年に1,243億8,000万ドルと評価され、2029年には2,569億ドルと予想されます。ミレニアム以降、バイオ医薬品分野は大きく進歩し、新薬やブロックバスター医薬品の開発が進んでいます。「医薬品受託開発製造機関(CDMO)」モデルは、需要の高まりに対応して登場しました。CDMOは、製薬会社の生産プロセスの開発と製造を専門とし、医薬品製造の全過程をサポートします。これらの事業体は、主に医薬品有効成分(API)の製造に重点を置いており、過去10年間に合併や買収により急増しています。大手製薬会社は社内の能力を選択するかもしれませんが、中小企業はCDMOのアウトソーシングを選び、投資リスクを軽減し、専門知識へのアクセスを提供します。この傾向は、医薬品開発の取り組みの効率と成功を高めます。

mRNA技術などの革新的なモダリティの台頭により、CDMOは進化する医薬品ニーズを満たすために最先端の製造能力に投資するようになりました。さらに、製薬会社による業務の合理化とコスト削減のためのアウトソーシングの増加が、CDMOセクターを後押ししています。開発の初期段階から商業生産まで、専門的なサービスの重要性が高まっていることから、医薬品開発のライフサイクル全体におけるCDMOの役割が確実に拡大しています。さらに、デジタル技術やデータ分析の進歩と相まって、柔軟でスケーラブルな製造プロセスの重視がCDMO市場の将来の方向性を示し、多様で複雑な医薬品要件を満たすための効率性と適応性を提供しています。世界のCDMO市場は、2024年から2029年にかけて12.85%のCAGRで成長すると予想されます。

レポート詳細

目次

Table of Contents

1. Executive Summary

2. Introduction

2.1 Contract Development and Manufacturing Organization (CDMO): An Overview
2.1.1 CDMO Value Chain Overview

2.2 CDMO Segmentation: An Overview
2.2.1 CDMO Segmentation

3. Global Market Analysis

3.1 Global CDMO Market: An Analysis

3.1.1 Global Contract Development and Manufacturing Organization (CDMO) Market: An Overview
3.1.2 Global CDMO Market by Value
3.1.3 Global CDMO Market by Type (Chemical Drugs and Biologics)
3.1.4 Global CDMO Market by Product (API/Bulk Drugs, Drug Product Manufacturing (Inc. Dosage & Formulation Development) and Packaging)
3.1.5 Global CDMO Market by Sourcing (In House and Outsourced)
3.1.6 Global CDMO Market by Application (Oncology, Cardiovascular Disease, Diabetes, Hormonal, Glaucoma and Others)
3.1.7 Global CDMO Market by Region (North America, Europe, Asia Pacific, and Rest of the World (ROW))

3.2 Global CDMO Market: Type Analysis

3.2.1 Global CDMO Market By Type: An Overview
3.2.2 Global Chemical Drugs CDMO Market By Value
3.2.3 Global Biologics CDMO Market By Value

3.3 Global CDMO Market: Product Analysis

3.3.1 Global CDMO Market By Product: An Overview
3.3.2 Global API/Bulk Drugs CDMO Market By Value
3.3.3 Global Drug Product Manufacturing (Inc. Dosage & Formulation Development) CDMO Market By Value
3.3.4 Global Packaging CDMO Market By Value

3.4 Global CDMO Market: Sourcing Analysis

3.4.1 Global CDMO Market By Sourcing: An Overview
3.4.2 Global In House CDMO Market By Value
3.4.3 Global Outsourced CDMO Market By Value

3.5 Global CDMO Market: Application Analysis

3.5.1 Global CDMO Market By Application: An Overview
3.5.2 Global Oncology CDMO Market By Value
3.5.3 Global Cardiovascular Disease CDMO Market By Value
3.5.4 Global Diabetes CDMO Market By Value
3.5.5 Global Hormonal CDMO Market By Value
3.5.6 Global Glaucoma CDMO Market By Value
3.5.7 Global Other CDMO Applications Market By Value

4. Regional Market Analysis

4.1 Asia Pacific CDMO Market: An Analysis

4.1.1 Asia Pacific CDMO Market: An Overview
4.1.2 Asia Pacific CDMO Market by Value
4.1.3 Asia Pacific CDMO Market by Region (China, Japan, India, and Rest of Asia Pacific)
4.1.4 China CDMO Market by Value
4.1.5 China CDMO Market by Type (Chemical Drugs and Biologics)
4.1.6 China Chemical Drugs CDMO Market by Value
4.1.7 China Biologics CDMO Market by Value
4.1.8 Japan CDMO Market by Value
4.1.9 India CDMO Market by Value
4.1.10 Rest of Asia Pacific CDMO Market by Value

4.2 North America CDMO Market: An Analysis

4.2.1 North America CDMO Market: An Overview
4.2.2 North America CDMO Market by Value
4.2.3 North America CDMO Market by Region (the US, Canada and Mexico)
4.2.4 The US CDMO Market by Value
4.2.5 The US CDMO Market by Product (API/Bulk Drugs, Drug Product Manufacturing (Inc. Dosage & Formulation Development) and Packaging)
4.2.6 The US API/Bulk Drugs CDMO Market By Value
4.2.7 The US Drug Product Manufacturing (Inc. Dosage & Formulation Development) CDMO Market By Value
4.2.8 The US Packaging CDMO Market By Value
4.2.9 Canada CDMO Market by Value
4.2.10 Mexico CDMO Market by Value

4.3 Europe CDMO Market: An Analysis

4.3.1 Europe CDMO Market: An Overview
4.3.2 Europe CDMO Market by Value
4.3.3 Europe CDMO Market by Region (Germany, United Kingdom, France, and Rest of the Europe)
4.3.4 Germany CDMO Market by Value
4.3.5 United Kingdom CDMO Market by Value
4.3.6 France CDMO Market by Value
4.3.7 Rest of Europe CDMO Market by Value

4.4 Rest of the World CDMO Market: An Analysis

4.4.1 Rest of the World CDMO Market: An Overview
4.4.2 Rest of the World CDMO Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19
5.1.1 Surge in Contracts to CDMOs

5.2 Post-COVID Scenario

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Aging Population
6.1.2 Rising Healthcare Expenditure
6.1.3 Increasing Pharmaceutical R&D Expenses
6.1.4 Escalating Demand for Active Pharmaceutical Ingredient (API)
6.1.5 Surge in Outsourcing Trends
6.1.6 Rising Prevalence of Genetic Disorders

6.2 Challenges
6.2.1 Biotech Funding Issues
6.2.2 Varying Regulatory Requirements Across Regions
6.2.3 Dependence on Patents, Copyrights, Trademarks and Trade Secrets

6.3 Market Trends
6.3.1 Growing Biologics Market
6.3.2 Rising Development of Small Molecule Drugs
6.3.3 Bringing Orphan Drugs to Market
6.3.4 Emerging Markets
6.3.5 Rise in Investments and Strategic Collaborations
6.3.6 Technological Advancement in the CDMO

7. Competitive Landscape

7.1 Global CDMO Market Players: Competitive Landscape
7.2 Global Biologics CDMO Players by Market Share
7.3 Asian CDMO Players by Current Capacity
7.4 Global CDMO Players: Key Developments

8. Company Profiles

8.1 Catalent Pharma Solutions Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategy

8.2 Samsung Biologics Co. Ltd.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategy

8.3 WuXi AppTec
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategy

8.4 Boehringer Ingelheim
8.4.1 Business Overview
8.4.2 Net Sales by Businesses
8.4.3 Business Strategy

8.5 WuXi Biologics (Cayman) Inc.
8.5.1 Business Overview
8.5.2 Operating Regions
8.5.3 Business Strategy

8.6 Jubilant Pharmova Limited
8.6.1 Business Overview
8.6.2 Operating Segments

8.7 Lonza Group AG
8.7.1 Business Overview
8.7.2 Operating Segments
8.7.3 Business Strategy

8.8 Siegfried Holding AG
8.8.1 Business Overview
8.8.2 Net Sales by Product Group
8.8.3 Business Strategy

8.9 Thermo Fisher Scientific Inc.
8.9.1 Business Overview
8.9.2 Operating Segments
8.9.3 Business Strategies

8.10 FUJIFILM Holdings Corporation
8.10.1 Business Overview
8.10.2 Operating Segments
8.10.3 Business Strategy

8.11 Recipharm AB
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 Bushu Pharmaceuticals Ltd.
8.12.1 Business Overview
8.12.2 Business Strategy

8.13 Piramal Group (Piramal Pharma Solutions)
8.13.1 Business Overview
8.13.2 Business Strategy

List of Figures
Figure 1: Benefits Of CDMO
Figure 2: CDMO Segmentation
Figure 3: Global CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 4: Global CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 5: Global CDMO Market by Type; 2023 (Percentage, %)
Figure 6: Global CDMO Market by Product; 2023 (Percentage, %)
Figure 7: Global CDMO Market by Sourcing; 2023 (Percentage, %)
Figure 8: Global CDMO Market by Application; 2023 (Percentage, %)
Figure 9: Global CDMO Market by Region; 2023 (Percentage, %)
Figure 10: Global Chemical Drugs CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 11: Global Chemical Drugs CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 12: Global Biologics CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 13: Global Biologics CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 14: Global API/Bulk Drugs CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 15: Global API/Bulk Drugs CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 16: Global Drug Product Manufacturing (Inc. Dosage & Formulation Development) CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 17: Global Drug Product Manufacturing (Inc. Dosage & Formulation Development) CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 18: Global Packaging CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 19: Global Packaging CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 20: Global In House CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 21: Global In House CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 22: Global Outsourced CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 23: Global Outsourced CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 24: Global Oncology CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 25: Global Oncology CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 26: Global Cardiovascular Disease CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 27: Global Cardiovascular Disease CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 28: Global Diabetes CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 29: Global Diabetes CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 30: Global Hormonal CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 31: Global Hormonal CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 32: Global Glaucoma CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 33: Global Glaucoma CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 34: Global Other CDMO Applications Market By Value; 2019-2023 (US$ Billion)
Figure 35: Global Other CDMO Applications Market By Value; 2024-2029 (US$ Billion)
Figure 36: Asia Pacific CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 37: Asia Pacific CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 38: Asia Pacific CDMO Market by Region; 2023 (Percentage, %)
Figure 39: China CDMO Market by Value, 2019-2023 (US$ Billion)
Figure 40: China CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 41: China CDMO Market by Type; 2023 (Percentage, %)
Figure 42: China Chemical Drugs CDMO Market by Value, 2019-2023 (US$ Billion)
Figure 43: China Chemical Drugs CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 44: China Biologics CDMO Market by Value, 2019-2023 (US$ Billion)
Figure 45: China Biologics CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 46: Japan CDMO Market by Value, 2019-2023 (US$ Billion)
Figure 47: Japan CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 48: India CDMO Market by Value, 2019-2023 (US$ Billion)
Figure 49: India CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 50: Rest of Asia Pacific CDMO Market by Value, 2019-2023 (US$ Billion)
Figure 51: Rest of Asia Pacific CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 52: North America CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 53: North America CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 54: North America CDMO Market by Region; 2023 (Percentage, %)
Figure 55: The US CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 56: The US CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 57: The US CDMO Market by Product; 2023 (Percentage, %)
Figure 58: The US API/Bulk Drugs CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 59: The US API/Bulk Drugs CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 60: The US Drug Product Manufacturing (Inc. Dosage & Formulation Development) CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 61: The US Drug Product Manufacturing (Inc. Dosage & Formulation Development) CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 62: The US Packaging CDMO Market By Value; 2019-2023 (US$ Billion)
Figure 63: The US Packaging CDMO Market By Value; 2024-2029 (US$ Billion)
Figure 64: Canada CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 65: Canada CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 66: Mexico CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 67: Mexico CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 68: Europe CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 69: Europe CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 70: Europe CDMO Market by Region; 2023 (Percentage, %)
Figure 71: Germany CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 72: Germany CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 73: United Kingdom CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 74: United Kingdom CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 75: France CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 76: France CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 77: Rest of Europe CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 78: Rest of Europe CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 79: Rest of the World CDMO Market by Value; 2019-2023 (US$ Billion)
Figure 80: Rest of the World CDMO Market by Value; 2024-2029 (US$ Billion)
Figure 81: Global Percentage of Population Aged 65 Years or Above; 2022, 2030 & 2050 (Percentage, %)
Figure 82: Global Healthcare Expenditure as a Percentage of GDP; 2022 (Percentage, %)
Figure 83: Global Pharmaceutical R&D Expenses; 2017-2026 (US$ Billion)
Figure 84: Global Biotech Sector Annual Capital Raised; 2020-2022 (US$ Million)
Figure 85: Global Biologics Market; 2021-2030 (US$ Billion)
Figure 86: Global Number of Small Molecule Drugs Entering the Development Pipeline; 2016-2028 (Thousand)
Figure 87: Global Biologics CDMO Players by Market Share; 2023 (Percentage,%)
Figure 88: Selected Asian Biologics CDMO Companies by Current Capacity; 2021-2026 (Kilo Litre (kL)
Figure 89: Catalent, Inc. Net Revenue by Segments; 2023 (Percentage, %)
Figure 90: Samsung Biologics Co. Ltd. Revenue by Segments; 2022 (Percentage, %)
Figure 91: WuXi AppTec Revenue by Business Segments; 2022 (Percentage, %)
Figure 92: Boehringer Ingelheim Net Sales by Businesses; 2022 (Percentage, %)
Figure 93: WuXi Biologics (Cayman) Inc. Revenue by Regions; 2022 (Percentage, %)
Figure 94: Jubilant Pharmova Limited Revenue by Segments; 2023 (Percentage, %)
Figure 95: Lonza Group AG Sales by Segments; 2022 (Percentage, %)
Figure 96: Siegfried Holding AG Net Sales by Product Group; 2022 (Percentage, %)
Figure 97: Thermo Fisher Scientific Inc. Revenue by Segment; 2022 (Percentage, %)
Figure 98: FUJIFILM Holdings Corporation Revenue by Segment; 2022 (Percentage, %)
Table 1: CDMO Value Chain Overview
Table 2: Contracts Placed with Pharmaceutical CDMOs; 2020

この商品のレポートナンバー

0000037443

TOP